<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01084785</url>
  </required_header>
  <id_info>
    <org_study_id>08-06-23/01</org_study_id>
    <nct_id>NCT01084785</nct_id>
    <nct_alias>NCT00157352</nct_alias>
    <nct_alias>NCT00157365</nct_alias>
    <nct_alias>NCT00157391</nct_alias>
    <nct_alias>NCT00157404</nct_alias>
    <nct_alias>NCT00157417</nct_alias>
    <nct_alias>NCT00157430</nct_alias>
    <nct_alias>NCT00157443</nct_alias>
    <nct_alias>NCT00157456</nct_alias>
    <nct_alias>NCT00157469</nct_alias>
    <nct_alias>NCT00157495</nct_alias>
    <nct_alias>NCT00181337</nct_alias>
    <nct_alias>NCT00181376</nct_alias>
    <nct_alias>NCT00181389</nct_alias>
    <nct_alias>NCT00181402</nct_alias>
    <nct_alias>NCT00181415</nct_alias>
    <nct_alias>NCT00181428</nct_alias>
    <nct_alias>NCT00181441</nct_alias>
    <nct_alias>NCT00181454</nct_alias>
    <nct_alias>NCT00181467</nct_alias>
    <nct_alias>NCT00181480</nct_alias>
    <nct_alias>NCT00181493</nct_alias>
    <nct_alias>NCT00181519</nct_alias>
    <nct_alias>NCT01067872</nct_alias>
  </id_info>
  <brief_title>Biobank Carcinoma: Storing Blood and Protein of Patients With Cancer</brief_title>
  <acronym>Biobank</acronym>
  <official_title>Storing Blood for Analysis of DNA and Protein of Patients With Cancer in MAASTRO Clinic</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maastricht Radiation Oncology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Maastricht University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Maastricht Radiation Oncology</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine, by means of DNA and protein analysis, the
      relationship between DNA and protein profiles and a number of endpoints, which are important
      for the patient such as overall survival and side effects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It has already been known for a long time that cancer is a genetic disorder and that the
      development of the illness is a very complex interaction between genetic and surrounding
      factors. Also the response on therapy and the development and seriousness of side effects is
      stipulated by this complicated collaboration of genetic and surrounding factors. Moreover it
      is not only the DNA that plays an important role but also the systems of control at protein
      level. At this moment a lot of questions remain to be answered because up till now the
      studies were of rather restricted statistic strength with frequently inconsistent dates and
      moreover retrospective. Major retrospective studies are necessary to distinguish the
      relationship between DNA/protein patterns and clinical relevant endpoints like prognosis and
      toxicity in which an as broad as possible patient group is being monitored. For this reason
      we want to take blood samples in MAASTRO clinic of all patients with lung cancer and to store
      it encrypted so that we can perform DNA and protein analyses in future and to correlate the
      results with survival and toxicity of the treatment.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2003</start_date>
  <completion_date type="Anticipated">January 2025</completion_date>
  <primary_completion_date type="Anticipated">January 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <enrollment type="Anticipated">10000</enrollment>
  <condition>Cancer</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      whole blood
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        primary care clinic
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  cancer

        Exclusion Criteria:

          -  not able to comply with follow-up
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dirk De Ruysscher, Prof PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CCMO</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Philippe Lambin, Prof PHD</last_name>
    <phone>31 (0) 088 44 55 666</phone>
    <email>philippe.lambin@maastro.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dirk De Ruysscher, Prof PHD</last_name>
    <phone>31 (0) 088 44 55 666</phone>
    <email>dirk.deruysscher@maastro.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Maastricht Radiation Oncology</name>
      <address>
        <city>Maastricht</city>
        <state>Limburg</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dirk De Ruysscher, Prof PHD</last_name>
      <phone>31 (0) 88 44 55 666</phone>
      <email>dirk.deruysscher@maastro.nl</email>
    </contact>
    <contact_backup>
      <last_name>Philippe Lambin, Prof PHD</last_name>
      <phone>31 (0) 88 44 55 666</phone>
      <email>philippe.lambin@maastro.nl</email>
    </contact_backup>
    <investigator>
      <last_name>Dirk De Ruysscher, Prof PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 10, 2010</study_first_submitted>
  <study_first_submitted_qc>March 10, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 11, 2010</study_first_posted>
  <last_update_submitted>May 23, 2016</last_update_submitted>
  <last_update_submitted_qc>May 23, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 24, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cancer</keyword>
  <keyword>genomics</keyword>
  <keyword>proteomics</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

